Screener
CRISPR Therapeutics CRSP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Deferred revenue, current | 15,344 | 15,771 |
| Accrued tax liabilities | 638 | 1,113 |
| Operating lease liabilities | 18,612 | 18,578 |
| Other current liabilities | 13,113 | 13,113 |
| Total current liabilities | 136,286 | 149,120 |
| Long-term debt | 585,470 | — |
| Operating lease liabilities, net of current portion | 183,560 | 188,168 |
| Other non-current liabilities | 5,948 | 6,142 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's accrued expenses?
- CRISPR Therapeutics (CRSP) reported accrued expenses of $13.11M in Q1 2026.
- What is the long-term trend for CRISPR Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's accrued expenses has grown at a 12.7% compound annual growth rate (CAGR), from $7.21M to $13.11M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about CRISPR Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude